Purpose: Patients with hypoplastic left heart syndrome (HLHS) and its variants following palliation surgery are at risk for thrombosis. This study examines variability of antithrombotic practice, the incidence of interstage shunt thrombosis and other adverse events following Stage I and Stage II palliation within the National Pediatric Cardiology Quality Improvement Collaborative (NPC-QIC) registry. 
Introduction
Hypoplastic left heart syndrome remains one of the most complex and challenging of congenital heart diseases. A three stage surgical palliation has become the standard of care for these patients. Stage I palliation consists of the standard Norwood procedure combined with a BlalockTaussig (BT) shunt, right ventricular to pulmonary artery (RV to PA) conduit or central shunt. 1 Of late, the hybrid procedure has emerged as an alternative to the standard stage I palliative procedures and includes placement of pulmonary artery bands and a ductus arteriosus stent. 1 2 This is followed by Stage II palliation comprising of a superior-cavopulmonary anastomosis and then the final stage of palliation comprising of a Fontan procedure. Patients who have undergone the hybrid procedure undergo a comprehensive stage II procedure comprising of removal of the PA bands with possible PA reconstruction, removal of the PDA stent with aortic arch reconstruction, a Damus-Kaye-Stansel connection of the aortic and PA roots, a bidirectional superior cavopulmonary connection, and an atrial septectomy. 2 Despite advances in surgical techniques and peri-operative monitoring, the early mortality rate for these patients remain high, ranging from 4 to15%. 3 4 The national mortality rate for patients undergoing the Norwood operation is 1 in 5 patients and this varies based on center and surgical volume. [5] [6] [7] [8] [9] [10] The time between discharge from the hospital following Stage I palliation and presentation for Stage II palliation (also referred to as the interstage period), poses risk due to hemodynamic instability with high mortality rates attributed to several factors. These include low birth weight, genetic syndromes, greater than moderate ventricular dysfunction, greater than moderate atrioventricular valve regurgitation, restrictive or intact atrial septum, recoarctation of the aortic arch, obstruction of pulmonary arteries or the shunt, delayed age at surgery, longer cardiopulmonary bypass times and postoperative renal dysfunction. 4 6 One of the potentially fatal complications following Stage I palliation is thrombosis of the systemic to pulmonary shunt. [11] [12] [13] The nature of the Stage I surgery, small infant size, shunt size as well as abnormalities of the coagulation cascade and platelet function due to cardiopulmonary bypass places these patients at risk for shunt thrombosis. [14] [15] [16] [17] [18] [19] BT shunt thrombotic occlusion rates ranging from 1-17% have been noted in previous studies. 11 20 21 The occlusion can occur during the immediate post-operative period as well during the interstage period . The use of routine thromboprophylaxis has been advocated but there is still a lack of conclusive evidence about its risk versus benefits. 14 22 23 The purpose of our study was to evaluate variability in antithrombotic practices at discharge following Stage I and Stage II surgery. The secondary aim of our study was to assess the incidence of interstage shunt thrombosis and other thrombosis related morbidity and mortality such as seizures, stroke, cardiac arrest and need for cardiac catheterization during interstage in relation to discharge antithrombotic treatment.
Materials and Methods
This was a multicenter retrospective chart review using the NPC-QIC registry database. The NPC-QIC Improvement Collaborative registry is a secure, web-based system (REDCap, Vanderbilt University) with data voluntarily entered by participating centers in the United
States. 24 
Results

Patient population
A total of 932 standard Stage I patients were included in the study. This group was predominantly males (62%) and Caucasian (74%) with HLHS being the most common diagnosis (68%) ( Table 1 ). The majority (56%) of these patients underwent a Norwood procedure with RV to PA conduit with 41% undergoing Norwood procedure with BT shunt. The remaining 3% of patients received central shunts or RV to PA conduits but were classified as "other". population and the most common diagnosis being HLHS (67%) ( Table 1) . Surgical centers with >10 patient enrollment in the NPC-QIC database were included during assessment of inter-site variability. Centers with <10 patient enrollment were excluded from intersite variability analysis. The antithrombotic medications were classified into the following groups: aspirin only, enoxaparin only, clopidogrel only, warfarin only, combination therapy (aspirin + at least one of the other drugs) and no antithrombotic. Although the mechanisms of action for these medications are different, for ease of reading, all of the above medications will be referred to as "discharge antithrombotic or antithrombotic regimen" from this point onwards.
Stage I discharge regimen: Aspirin was the most frequently used anti-thrombotic and was also the most frequently used solitary drug of choice in 87% of total patients (Table 2 ).
Approximately 7% of the patients were discharged on a multidrug antithrombotic regimen consisting of aspirin with or without clopidogrel and/ or warfarin and/ or enoxaparin. Hence approximately 93.8% of patients were discharged on aspirin either as single or part of multidrug regimen. Four percent of the patients were sent home with no antithrombotic. Aspirin was the most common discharge anti-coagulant irrespective of whether the patient had a RV to PA conduit (88%) or a BT shunt (86%) placed. A separate analysis of the hybrid patients following comprehensive stage II was also performed.
There were a total of 64 hybrids patients identified after Stage II and it was noted that a larger proportion of these patients (22 of 64 or 34.4%) were discharged on enoxaparin when compared to the non hybrid / standard patients (21 or 2.5%). 31% (20/64) were discharged on aspirin and almost 20% (13 of 64) went home without thromboprophylaxis.
Intersite variability: Inter-site variability on the choice of antithrombotic following standard Stage I and Stage II palliation is shown in Figures 2 and 3 . Although the majority of the Stage I sites used aspirin as the choice of antithrombotic therapy at discharge, there were a few sites where up to 50% of the patients were discharged either on no antithrombotics or non-aspirin antithrombotic therapy. In addition, several sites discharged a significant number of their patients on combination medications. There was more intersite variability noted following Stage II palliation as noted in Figure 3 . Although aspirin was still the most frequently used medication at the time of discharge, there were sites where the vast majority of the patients were discharged on no antithrombotics and many sites where patients were discharged on enoxaparin or combination therapy.
Interstage Shunt thrombosis and other adverse outcomes
Interstage shunt thrombosis was identified in three patients (Table 3 ). All 3 patients underwent
Stage I palliation with a BT shunt and were discharged on aspirin. Data is limited in terms of their clinical presentation but all 3 patients were readmitted with shunt thrombosis, which was confirmed by cardiac catheterization during that admission. The first patient was taken to surgery for central shunt placement with pulmonary artery augmentation. Ultimately the patient was not considered a satisfactory Stage II candidate and was withdrawn from the registry. The second patient had a stroke following shunt thrombosis and care was withdrawn. The third patient required ECMO and eventually underwent Stage II surgery.
Other adverse outcomes such as stroke, seizure and cardiac arrest were identified, and their discharge antithrombotic was evaluated (Table 3 ). A total of 11 patients were identified with cardiac arrest and 2 with stroke. All patients with cardiac arrest were discharged home on aspirin. Two patients had seizures of which one was sent home on aspirin and the other went home on no antithrombotic. Two patients suffered from stroke, the first discharged on clopidogrel and the other on enoxaparin.
Of the 69 patients who died during the interstage, 63 (91%) were discharged home on aspirin and the remaining 3 (4%) were on combination medications, 2 were on no antithrombotic (3%) and 1 was on enoxaparin (1.5%).
Interstage cardiac catheterization
A total of 44 patients (5% of total Stage I patients) were readmitted during the interstage period for BT shunt or RV to PA conduit dilation and /or stenting via cardiac catheterization. Thirtyseven of the 44 patients were sent home on aspirin at the time of Stage I discharge. This accounted for 4.5 % of the total patients (N=809) who went home on aspirin only (Table 4) .
Discussion
Despite several advances in the management of single ventricle Norwood palliated patients, there continues to be significant morbidity and reported mortality rates. Thrombosis of the systemic to pulmonary artery shunt is one of the potentially life threatening complication in these patients following Stage I palliation. 3 4 Therefore maintaining patency of the BT shunt or the RV to PA conduit is of utmost importance. 11 18 The use of routine thromboprophylaxis has been advocated, but there is still lack of conclusive evidence regarding choice of medications, route, dosage and its impact on clinical outcomes. One of the largest prospective multicenter studiesfrom Fenton et al concluded that aspirin use decreased the risk of shunt thrombosis and its associated morbidity and mortality. 11 In the American Heart Association consensus statement for prevention and treatment of thrombosis in pediatric and congenital heart disease Giglia et al recommended long term use of low dose aspirin for prevention of long term thrombosis of systemic to pulmonary artery shunts in the absence of increased risk of bleeding (Class I; level of evidence B). 22 In 2013, Wessel et al found during a prospective randomized trial of Clopidogrel in infants with shunts that, 88% were being treated with aspirin. 23 However we were unable to assess these factors due to unavailability of such data in the registry.
There was a relatively low rate of shunt related complications in this patient group during the interstage study period (<1%). This was lower compared to other studies where shunt occlusion rates in the immediate post-operative phase ranged from 4-15% 20 21 . We also suspect that the percentage of mortality that can be attributed to shunt thrombosis and its consequences may be underestimated since there is often a lack of histopathologic evidence for shunt thrombosis at the time of death due to lack of autopsies in all patient deaths. Side effect profile, variable pharmacokinetic profile, requirement of expertise for close monitoring for drug levels for heparin and warfarin may also play an important role in the decision making. It is also acknowledged that the optimal dose of aspirin has not been determined and pediatric patients have been shown to demonstrate aspirin resistance at doses currently being utilized 27 . Recent evidence for the optimal aspirin dosing and aspirin resistance is currently being evaluated with utilization of thromboelastography (TEG) with platelet mapping, aspirin resistance testing, and urine thromboxane levels. 28 29 It is interesting to note that all patients except one who suffered adverse outcomes from thrombosis were on antithrombotic at discharge. However information on dose of medication or compliance at home was not available through the database.
Limitations
This study is limited by its retrospective nature. The overall rate of shunt thrombosis and other morbidities were rare in the interstage period. Therefore it was not possible to identify a definite association with medical management choices. Lack of data on why medications were prescribed made it difficult to understand the reasoning behind therapeutic choices. Immediate postoperative Norwood associated shunt thrombosis and thrombotic complications are not reported in this database thereby limiting this descriptive review. Only 38 of the 69 patients who died had autopsies and therefore the total number of shunt thrombosis may have been an underestimate.
Conclusions
Aspirin is by far the most common choice for thromboprophylaxis following Stage I and Stage II palliation. Clopidogrel, enoxaparin and warfarin were also used, but infrequently or in addition to aspirin. Substantially more variation is noted in the type of discharge antithrombotic following Stage II palliation with 17.5% of patients going home on no thromboprophylaxis compared to 4% after Stage I.
Despite this study having a large number of interstage patients, the incidence of adverse outcomes such as shunt thrombosis was rare. Given this low number, no significant association between shunt thrombosis and type of thromboprophylaxis could be derived. Other thrombotic complications such as seizures, stroke also occurred, with low frequency. Prospective studies, collaborations with more centers, other research registries, and individualized dosing studies or monitoring could prove to be beneficial in providing more insight.
